Physician profile
Patrick Mulhall
NPI 1982997482
$2,581.20
in general payments reported to CMS, 2019-2025
22 companies · $1,488 in 2025
The $1,488 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12.25 · 2020: $24.86 · 2022: $32.08 · 2023: $134 · 2024: $891 · 2025: $1,488.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,512.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,512.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $651.13 | 2023-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $385.90 | 2023-2025 | Fasenra, Airsupra, Tezspire |
| Verona Pharma, INC. | $199.26 | 2025 | Ohtuvayre |
| Insmed, INC. | $180.85 | 2022-2025 | Arikayce, Brinsupri |
| Genzyme Corporation | $176.01 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $149.95 | 2023-2025 | Dupixent |
| Actelion Pharmaceuticals US, INC. | $146.42 | 2024-2025 | Uptravi, Opsumit, Opsynvi |
| Takeda Pharmaceuticals U.S.A., INC. | $119.37 | 2024-2025 | Aralast |
| United Therapeutics Corporation | $87.40 | 2024-2025 | Tyvaso, Tyvaso |
| Bayer Healthcare Pharmaceuticals INC. | $86.50 | 2024-2025 | |
| Jazz Pharmaceuticals INC. | $69.07 | 2023-2024 | Xywav |
| Amgen INC. | $59.67 | 2024-2025 | Tezspire |
| Harmony Biosciences LLC | $56.72 | 2024-2025 | |
| Ani Pharmaceuticals, INC. | $55.28 | 2025 | Purified Cortrophin Gel |
| Avadel Cns Pharmaceuticals, LLC | $35.61 | 2024 | Lumryz |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Advanced Respiratory, INC | $24.86 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.36 | 2024 | Ofev |
| Philips North America LLC | $18.62 | 2022 | |
| Vifor Pharma, INC. | $16.48 | 2025 | Veltassa |
| Mylan Specialty L.P. | $16.10 | 2024 | Yupelri |
| Pfizer INC. | $13.39 | 2024 | |
| Electromed, INC. | $12.25 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Mulhall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.